Clearside Biomedical, Inc. announced that it will conduct a randomized, controlled, double-masked, Phase 2b clinical trial, called ODYSSEY, in wet AMD participants. Based on the draft guidance on wet AMD drug development released on February 24, 2023, by the U.S. Food & Drug Administration (FDA), plan to adjust trial design to use on-label aflibercept dosing in the comparator arm of ODYSSEY. The company expects a seamless transition to this adjusted trial design and plan to open trial enrollment in the second quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | +0.72% | +3.70% | +19.66% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.66% | 105M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Announces Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Second Quarter of 2023